NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

NCT07683325 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrostenotic Crohn's Disease

Interventions

DRUG: Ontunisertib
DRUG: Ontunisertib
DRUG: Ontunisertib
DRUG: Placebo

Sponsor

Agomab Spain S.L.U.